Paper Details

  1. Home
  2. Paper Details

Review article: Linaclotide for the management of irritable bowel syndrome with constipation.

Author: LayerP, StanghelliniV

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article discusses the use of linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Linaclotide has recently been approved by the European Medicines Agency (EMA) and the US Food and Drug Administration for these conditions.
Paper Details　
Original Abstract of the Article :
Irritable bowel syndrome with constipation (IBS-C) represents a significant burden to patients and healthcare systems due to its prevalence and lack of successful symptomatic resolution with established treatment options. Linaclotide 290 μg has recently been approved by the European Medicines Agency...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305214/

データ提供：米国国立医学図書館（NLM）

Linaclotide: A Beacon of Hope for Irritable Bowel Syndrome with Constipation

Irritable bowel syndrome with constipation (IBS-C) can feel like a relentless desert of discomfort, leaving individuals yearning for relief. This research explores the potential of linaclotide, a novel drug specifically designed to treat IBS-C, offering a potential oasis of comfort.

The authors provide a comprehensive review of linaclotide, highlighting its recent approval for the treatment of moderate-to-severe IBS-C. They discuss its mechanism of action, focusing on its ability to stimulate fluid secretion in the gut, potentially alleviating constipation and improving bowel function. The authors' findings suggest that linaclotide could offer a promising treatment option for individuals suffering from IBS-C, providing a potential path to relief from this debilitating condition.

Navigating the Desert of IBS-C: A Potential Solution

This research offers a glimmer of hope for individuals struggling with IBS-C, providing a potential solution for alleviating the discomfort and restoring normalcy to their lives. The authors' findings suggest that linaclotide could offer a promising treatment option for IBS-C, potentially transforming the experience of this debilitating condition.

Finding Relief from IBS-C: A Journey Towards Well-being

The journey to managing IBS-C can be arduous, but this research offers a potential pathway to relief. The authors' findings suggest that linaclotide could offer a promising treatment option, potentially alleviating the discomfort and restoring normalcy to the lives of individuals suffering from this condition. By exploring this new treatment option and working closely with healthcare providers, individuals with IBS-C can embark on a journey toward better well-being.

Dr. Camel's Conclusion

This research is like a refreshing oasis in the desert of IBS-C, offering hope for a potential solution to this debilitating condition. The authors' findings suggest that linaclotide could offer a promising treatment option, potentially alleviating the discomfort and restoring normalcy to the lives of individuals suffering from IBS-C. The study reminds us that the journey to managing IBS-C is often filled with challenges, but with innovative treatments and collaborative care, we can find pathways to relief and a more comfortable life.

Date :
  1. Date Completed 2014-10-08
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24433216

DOI: Digital Object Identifier

PMC4305214

Related Literature

Article Analysis
・Side Effects of linaclotide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.